Issue #5 No images? Click here Issue #5Tuesday, 19 December 2023Dear Stakeholder, Welcome to the quarterly issue of the Australian Pathogen Genomics (AusPathoGen/APG) Program newsletter. As a reminder, our team will use these communications to keep you up to date on the latest news, as well as any events and opportunities that may be of interest to this community. We are pleased to wrap up another productive year of the program. Since the last quarterly issue of the newsletter, we have been able to conclude the final meetings for the foundational pathogen working groups with manuscripts well underway for Salmonella enterica, Shigella spp., Mycobacterium tuberculosis, and Escherichia coli (One Health). We would like to thank the lead postdocs and implementor groups who have been instrumental in pulling together and analysing national datasets, which will inform the establishment of national surveillance of the Year 1 foundational pathogens. We are excited to embark on Year 3 of AusPathoGen in 2024, which will see increased involvement from jurisdictions and engagement with Public Health Units (PHUs). Next year will mark the commencement of Phase 2, which focuses on the best approaches for translating findings to date from the foundational projects into implementation in partnership with the PHUs. We are also looking forward to the expansion of the program audience to increase advocacy, raise awareness of our activities, and engage with public health and policy decision makers to facilitate outcomes into action. This issue of the newsletter will provide:
Thank you to all our program partners for your contributions during working group meetings, the annual symposium, re-hosting the public health pathogen genomics webinar series, and all other meetings held in-between. We hope you have a safe and happy holiday season, and we look forward to building upon the momentum in 2024. Sincerely, The AusPathoGen Executive Group Highlights from 2023Pathogen UpdatesThis quarterly update will showcase the latest format we will be using for the pathogen updates. Previously, we had provided an in-depth review on a single pathogen each quarter, however with the increasing number of projects added to the program, we wanted to provide updates for all of them in a digestible format in each issue of the newsletter moving forward. As such, you can see the inclusion of an infographic associated with each pathogen to allow for you to view the progress at a glance, in addition to the written update from the relevant working groups (WGs). The key for how this can be read can be seen to the side, with the progress bar indicating which stage of the project the respective pathogen is at. 14,765Genomes contributed Initial examination of common serovars reveals clusters of closely related samples extending across various jurisdictions, and low antimicrobial resistance observed within the dataset. As of November 30, 2023, the datasets have been closed to allow for the bioinformatic analysis teams to finalise the analysis and commence manuscript preparation. Key priorities for the Salmonella enterica working group in the coming months include the second 3-month snapshot, commencing January 1 2024, and contributing toward the prospective collection of Typhi sequencing, with analysis planned for early 2024. 3,768Genomes contributed Changes in Shigella flexneri serotypes and Shigella sonnei types, both pre- and post-pandemic, have been noted. Shigella sonnei clusters were identified, some spanning multiple jurisdictions and others specific to certain jurisdictions. As with Salmonella enterica, the datasets were closed on November 30, 2023. Discussions within the WG meeting included the consideration of a potential definition for extensively drug-resistant (XDR) Shigella spp. to be applied in the AusPathoGen project. Further steps involve collaboration with stakeholders and end-users for the implementation of the findings. 6,343Genomes contributed The inclusion of supplementary retrospective sequences this quarter has allowed the genomic dataset to encapsulate 42% of all notified cases in Australia from 2015 to 2023. Discussions on the genomic prediction of Mycobacterium tuberculosis AMR have taken place, prompting the team to investigate further the current results. In the next quarter, the aim is to finalise the data analysis for the retrospective data with the advisory sub-working group. The team will also be actively seeking to engage further with PHUs and end-users involved in the project. Escherichia coli3,324Genomes contributed Identified across diverse hosts and environments, closely related Escherichia coli strains reveal intricate bacterial transmission networks between humans, pets, food, livestock, wildlife, and the environment. We have also identified shareable genetic elements ('plasmids') which promote their virulence capacity and AMR. WG meetings have been critical in shaping the prospective sampling regime, leveraging professional networks accessible to the AusPathoGen team. Retrospectively, two manuscripts are nearing submission, with two more in development. Ongoing prospective sampling remains a top priority. Invasive group A streptococcal disease1,178Genomes contributed The invasive group A streptococcal disease (iGAS) WG have now reviewed and endorsed the data analysis plan, which was developed collaboratively between the iGAS bioinformatic sub-WG. Priorities for the next quarter include completing the collation of retrospective datasets, continuing the 12-month national snapshot that commenced on 1 August 2023, and re-establishing the bioinformatic WG to commence the data analysis. Invasive pneumococcal diseaseN/AGenomes contributed The inaugural meeting of the invasive pneumococcal disease (IPD) WG was held on October 27, 2023. The distribution of terms of reference and metadata proforma to WG members for review marked the initiation of the collaborative effort. Activities included the commencement of data contribution, encompassing both retrospective and prospective data, and discussion to guide the development of a comprehensive data analysis plan in the future. Furthermore, a bioinformatic analysis group will be established to enhance the analytical aspects of the IPD project. Candida aurisN/AGenomes contributed The inaugural WG meeting on October 23rd fostered an engaging discussion on the distinctive laboratory and bioinformatics prerequisites for the project. Emphasising key priorities, the team aims to distribute a questionnaire, capturing laboratories' capacity for data contribution to both retrospective and snapshot studies. Simultaneously, efforts are underway to assemble the bioinformatics working group, ensuring a comprehensive approach to the project's laboratory and analytical needs. Evaluation of Whole Genome Sequencing Utility and Cost-EffectivenessIn the current phase of data collection for the Expert Elicitation and Situation Assessment surveys, the team is actively engaged. Notably, two impactful studies are on track for a rollout in the initial quarter of 2024, promising insights into the ongoing research endeavours. The upcoming quarter is marked by pivotal objectives. The team aims to submit a protocol paper for publication, ensuring the dissemination and publication of completed Expert Elicitation and Situation Assessment studies. Additionally, the initiation of impact evaluation case studies is scheduled, accompanied by the development of a protocol for an ethical-legal-social implications study, underscoring the team’s commitment to a holistic and responsible research approach. AusPathoGen presentations and postersAusPathoGen was presented by program partners on the following occasions in the last quarter:
AusPathoGen Working GroupsEstablished working groups under the program are listed below. If you wish to join a working group or would like further information, please email the AusPathoGen Secretariat.
AusPathoGen Progam PartnersAll previous newsletters are available to browse via the archive on our website. |